Tesamorelin / Ipamorelin Blend — GHRH (1-44) + GHSR Stack | Research Grade

The Tesamorelin + Ipamorelin blend pairs a 44-amino-acid GHRH analog with a selective GHRP in a single research vial — designed for researchers studying the synergistic GH release that occurs when GHRH and GHRP receptors are activated simultaneously.

Research-grade specs

• Components: Tesamorelin (GHRH) + Ipamorelin (GHRP)
• Combined mechanism: Dual receptor (GHRH-R + GHS-R1a) GH stimulation

Studied applications

• GHRH + GHRP synergy research
• Combined GH-pulse studies
• Body-composition research with dual mechanism
• Sleep / GH-release-pattern studies

Quality & trust

• ≥99% HPLC purity, third-party tested
• Mass spectrometry identity confirmation
• LAL endotoxin testing on every batch
• Batch-specific Certificate of Analysis included
• USA same-day shipping (orders before 2pm CT M-F)

Related research: Tesamorelin alone · Ipamorelin alone · CJC-1295 + Ipamorelin

Research literature

Tesamorelin AND Ipamorelin has been the subject of 3 peer-reviewed publications indexed in PubMed. Selected recent literature for research reference:

• Mendias CL et al. (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. PMID: 41966639
• Rahman OF et al. (2026). Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. PMID: 41490200
• Mayfield CK et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. PMID: 41476424

References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.